See more : Cognex Corporation (CGNX) Income Statement Analysis – Financial Results
Complete financial analysis of TC Biopharm (Holdings) Plc (TCBP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TC Biopharm (Holdings) Plc, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tibet Urban Development and Investment Co.,LTD (600773.SS) Income Statement Analysis – Financial Results
- Medical Imaging Corp. (MEDD) Income Statement Analysis – Financial Results
- C3is Inc. (CISS) Income Statement Analysis – Financial Results
- LifeClean International AB (publ) (LCLEAN.ST) Income Statement Analysis – Financial Results
- National Energy Services Reunited Corp (NESRW) Income Statement Analysis – Financial Results
TC Biopharm (Holdings) Plc (TCBP)
About TC Biopharm (Holdings) Plc
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 3.84M | 1.98M | 1.98M | 3.43M |
| Gross Profit Ratio | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 7.77M | 7.59M | 6.16M | 6.68M | 8.61M |
| General & Administrative | 6.47M | 8.34M | 3.11M | 2.21M | 3.01M |
| Selling & Marketing | 402.31K | 402.31K | 0.00 | 0.00 | 0.00 |
| SG&A | 6.87M | 8.74M | 3.11M | 2.21M | 3.01M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Cost & Expenses | 6.91M | 124.90K | 13.52M | 8.32M | 10.07M |
| Interest Income | 83.03K | 6.75M | 3.44M | 291.03K | 253.51K |
| Interest Expense | 0.00 | 6.75M | 3.44M | 292.06K | 275.41K |
| Depreciation & Amortization | 630.06K | 762.47K | 811.96K | 878.64K | 721.93K |
| EBITDA | -13.61M | -11.32M | -6.48M | -5.26M | -5.92M |
| EBITDA Ratio | 0.00% | -294.48% | -327.25% | -303.65% | -172.71% |
| Operating Income | -14.24M | -12.08M | -7.29M | -6.89M | -6.64M |
| Operating Income Ratio | 0.00% | -314.32% | -368.28% | -348.05% | -193.78% |
| Total Other Income/Expenses | 7.24M | 9.05M | -7.70M | -291.03K | -253.51K |
| Income Before Tax | -7.00M | -3.03M | -14.98M | -6.63M | -6.89M |
| Income Before Tax Ratio | 0.00% | -78.91% | -757.25% | -335.07% | -201.18% |
| Income Tax Expense | -1.09M | 1.72M | 1.41M | 1.17M | 826.07K |
| Net Income | -5.91M | -1.31M | -13.58M | -5.46M | -6.07M |
| Net Income Ratio | 0.00% | -34.17% | -686.12% | -275.84% | -177.07% |
| EPS | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| EPS Diluted | -191.21 | -382.31 | -6.95K | -2.88K | 0.00 |
| Weighted Avg Shares Out | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
| Weighted Avg Shares Out (Dil) | 30.89K | 3.44K | 1.95K | 1.89K | 1.89K |
TC BioPharm Intends to Launch Preclinical Studies for Treatment of Monkey Pox
EDINBURGH, Scotland , Sept. 6, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to...
TCBP Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
EDINBURGH, Scotland , Sept. 5, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications today announced it will participate at the...
TCBP Announces Dosing of 5 New Patients in ACHIEVE
5 New patients dosed, bringing total to 6 patients dosed in ACHIEVE at higher dose level 5 Patients received second dose 2 Patients received third dose EDINBURGH, Scotland , Sept. 3, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm"...
TC BioPharm Announces Closing of Upsized $6.0 Million Public Offering
EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of...
TC BioPharm Announces Grant of European Patent Covering Use of Modified Gamma Delta Cells for the Treatment of Cancer and Viral Indications
EDINBURGH, Scotland , Aug. 28, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has...
TC BioPharm Regains Compliance with Nasdaq Listing Rule 5550(b)
EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the Company...
TC BioPharm Announces Closing of $2.0 Million Public Offering
EDINBURGH, Scotland , Aug. 15, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the closing of...
Why Is TC BioPharm (TCBP) Stock Down 46% Today?
TC BioPharm (NASDAQ: TCBP ) stock is falling on Wednesday after the clinical-stage biopharmaceutical company announced the pricing of a registered direct offering of its shares. TC BioPharm is selling 2 million of its American Depository Shares (ADS) for $1 per...
TC BioPharm Announces Pricing of $2.0 Registered Direct Offering
EDINBURGH, Scotland , Aug. 13, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced it has entered...
TCBP Announces Plan to Implement ADS Ratio Change
EDINBURGH, Scotland , July 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will...
Source: https://incomestatements.info
Category: Stock Reports